Core Viewpoint - The article discusses the approval and potential of TQF3250, an oral GLP-1 receptor agonist developed by China National Pharmaceutical Group, for weight management and type 2 diabetes treatment, highlighting the growing global obesity crisis and the need for effective treatments [6][8]. Group 1: TQF3250 Development and Approval - TQF3250 has received FDA approval for clinical trials aimed at weight management and has also been accepted for trials in type 2 diabetes treatment by the NMPA in China [6]. - The drug is designed to selectively activate the cAMP-dependent GLP-1 receptor signaling pathway, promoting insulin secretion while minimizing gastrointestinal side effects, thus offering a differentiated advantage over existing injectable GLP-1 products [8]. Group 2: Global Obesity Trends - The global prevalence of overweight and obesity is projected to rise from 36% in 2000 to 50% by 2030, affecting nearly 3 billion people [6]. - In China, it is estimated that by 2025, 41% of adults will have a BMI ≥ 25 kg/m², with 9% classified as obese, leading to a projected 515 million adults with high BMI by 2030 [6]. Group 3: Health Implications of Obesity - In 2021, approximately 16 million premature deaths among adults were attributed to obesity-related diseases, with chronic non-communicable diseases accounting for 27% of the global disease burden [6]. - About 55% of premature deaths from type 2 diabetes are closely linked to obesity, indicating a significant gap in the supply of effective obesity management and treatment options [6].